Results for: VTX3232

Ventyx Biosciences (VTYX) received a strategic investment of $27 million from Sanofi, which will be used to support the company’s ongoing operations and advance its investigational drug, VTX3232, for neuroinflammatory and neurodegenerative diseases. In exchange, Sanofi gains exclusive rights to negotiate certain rights related to VTX3232’s clinical programs.

Sanofi has made a strategic investment of $27 million in Ventyx Biosciences, a company developing therapies for neuroinflammatory and neurodegenerative conditions. The investment will support the development of VTX3232, a promising drug candidate for Parkinson’s disease and obesity, with data expected in 2025.